Heartflow (NASDAQ:HTFL – Free Report) had its price objective hoisted by Stifel Nicolaus from $40.00 to $45.00 in a research note released on Friday, Marketbeat Ratings reports. Stifel Nicolaus currently has a buy rating on the stock.
A number of other analysts also recently issued reports on HTFL. Wells Fargo & Company boosted their price objective on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Robert W. Baird started coverage on shares of Heartflow in a research report on Friday, July 31st. They issued an “outperform” rating and a $34.00 price target for the company. William Blair initiated coverage on Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating for the company. Freedom Capital upgraded Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.43.
Check Out Our Latest Research Report on HTFL
Heartflow Price Performance
Heartflow (NASDAQ:HTFL – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.The company had revenue of $64.08 million during the quarter. Heartflow’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, equities analysts anticipate that Heartflow will post -0.82 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Heartflow news, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the sale, the insider directly owned 78,731 shares in the company, valued at $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $28.31, for a total value of $638,730.22. Following the completion of the sale, the chief executive officer directly owned 436,280 shares in the company, valued at approximately $12,351,086.80. This represents a 4.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 115,805 shares of company stock valued at $3,530,609. 7.70% of the stock is currently owned by insiders.
Institutional Trading of Heartflow
Several institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd acquired a new position in Heartflow during the fourth quarter worth about $27,000. Russell Investments Group Ltd. bought a new stake in shares of Heartflow during the 4th quarter valued at approximately $45,000. Essential Partners LLC acquired a new position in Heartflow during the 1st quarter worth approximately $57,000. Legal & General Group Plc bought a new position in Heartflow in the 3rd quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new stake in Heartflow in the fourth quarter valued at approximately $99,000.
Key Headlines Impacting Heartflow
Here are the key news stories impacting Heartflow this week:
- Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
- Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
- Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
- Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
- Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares
About Heartflow
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Stories
- Five stocks we like better than Heartflow
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
